SCHEMBL8415802

SCHEMBL8415802

CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC(C)[C@]4(C)[C@H]3CC[C@@]21C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 8/20 0.56
PGR P06401 7/20 0.56
LMNA P02545 6/20 0.56
SMN1; SMN2 Q16637 6/20 0.56
AR P10275 6/20 0.56
CYP3A4 P08684 5/20 0.56
NPSR1 Q6W5P4 4/20 0.56
ALDH1A1 P00352 3/20 0.56
SHBG P04278 3/20 0.56
ABCB11 O95342 2/20 0.56
CHRM2 P08172 2/20 0.56
CHRM1 P11229 2/20 0.56
USP2 O75604 2/20 0.56
ABCC4 O15439 1/20 0.56
ESR1 P03372 1/20 0.56
NR3C2 P08235 1/20 0.56
HRH2 P25021 1/20 0.56
AKR1C3 P42330 1/20 0.56
AKR1C2 P52895 1/20 0.56
AKR1C1 Q04828 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8415805 1.00 NR3C1 (0.56) NR3C1PGRLMNASMN1; SMN2AR
SCHEMBL11020426 0.90 AR (0.59) NR3C1PGRLMNASMN1; SMN2AR
SCHEMBL11022313 0.90 PGR (0.50) NR3C1PGRLMNASMN1; SMN2AR
SCHEMBL10716868 0.90 PGR (0.53) NR3C1PGRLMNASMN1; SMN2AR
SCHEMBL11024225 0.88 PGR (0.71) NR3C1PGRLMNASMN1; SMN2AR
SCHEMBL3029696 0.83 LMNA (0.67) NR3C1PGRLMNASMN1; SMN2AR
SCHEMBL5697475 0.83 NR3C1 (0.46) NR3C1PGRLMNASMN1; SMN2AR
SCHEMBL13941349 0.82 SMN1; SMN2 (0.74) NR3C1PGRLMNASMN1; SMN2AR
SCHEMBL29766827 0.82 SMN1; SMN2 (0.74) NR3C1PGRLMNASMN1; SMN2AR
SCHEMBL260024 0.82 SMN1; SMN2 (0.74) NR3C1PGRLMNASMN1; SMN2AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5861387-A TREATMENT AND PREVENTION OF BREAST AND ENDOMETRIAL CANCER, BONE LOSS, AND FOR TREATING ENDOMETRIOSIS ENDORECHERCHE INC. (CA) 1999-01-19 US disclosed
US-5846960-A Methods for preventing and treating osteoporosis with low dose non-masculinizing androgenic compounds ENDORECHERCHE, INC. (CA) 1998-12-08 US disclosed
US-5814340-A TREATMENT AND PREVENTION OF ESTROGEN-RELATED DISEASES, AND OF FERTILITY CONTROL ENDORECHERCHE INC. (CA) 1998-09-29 US disclosed
US-5753639-A ADMINISTERING LOW DOSE OF ANDROGENIC STEROID HAVING REDUCED SIDE EFFECTS ENDORECHERCHE INC. (CA) 1998-05-19 US disclosed
EP-0591311-B1 CONTROLLED RELEASE SYSTEMS AND LOW DOSE ANDROGENS ENDORECHERCHE INC (CA) 1997-12-17 EP disclosed
US-5629303-A ANTITUMOR AGENTS, SIDE EFFECT REDUCTION ENDORECHERCHE INC. (CA) 1997-05-13 US disclosed
US-5567695-A SIDE EFFECT REDUCTION ENDORECHERCHE, INC. (CA) 1996-10-22 US disclosed
US-5545634-A THERAPY, PREVENTION OF BREAST AND ENDOMETRIAL CANCER ENDORECHERCHE, INC. (CA) 1996-08-13 US disclosed
US-5541172-A ADMINISTERING ANDRONGENIC STEROIDS FROM MEDROXYPROGESTERONE ACETATE OR MEGESTROL ACETATE WITH BINDER ENDORECHERCHE, INC. (CA) 1996-07-30 US disclosed
US-5434146-A Antitumor, breast cancer ENDORECHERCHE, INC. (CA) 1995-07-18 US disclosed
US-5362720-A Monitoring and controlling low serum concentration of synthetic progesterone derivative to reduce side effects ENDORECHERCHE, INC. (CA) 1994-11-08 US disclosed
EP-0591311-A1 CONTROLLED RELEASE SYSTEMS AND LOW DOSE ANDROGENS ENDORECHERCHE INC. (CA) 1994-04-13 EP disclosed
WO-1993000070-A1 CONTROLLED RELEASE SYSTEMS AND LOW DOSE ANDROGENS ENDORECHERCHE INC. (CA) 1993-01-07 WO disclosed